Otsuka Pharmaceutical Europe and Lundbeck have announced that the European Commission has approved Rxulti (brexpiprazole) for ...

Leiden, the Netherlands, March 13, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) presents its preliminary (unaudited) financial report for the ...

Europe’s drug regulatory agency has given Kizfizo a negative opinion for the second time, following one from November 2024.

Orphelia Pharma is exploring alternative regulatory pathways for KIZFIZO after receiving a negative opinion from the ...

Uppsala University announced today that BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) two founders, Lars Lannfelt and Pär Gellerfors, ...

The latest decision makes Ionis/AstraZeneca's Wainzua the only approved drug in the EU for ATTRv-PN that can be self-administered monthly via an auto-injector.

SHELTON, CT / ACCESS Newswire / March 11, 2025 / NanoViricides, Inc. (the "Company")(NYSE American:NNVC), a clinical-stage global leader developing revolutionary broad-spectrum antiviral drugs that ...

DelveInsight's "BAVENCIO Market Size, Forecast, and Market Insight Report" highlights the details around BAVENCIO, a human ...

Ionis Pharmaceuticals (IONS) announced that Ionis and AstraZeneca’s (AZN) WAINZUA eplontersen has been approved in the European Union EU for ...

Novartis (NVS) shareholders agreed to the board of directors’ recommendations for all proposed resolutions at the company’s Annual General ...

The audited financial statements for the year ended December 31, 2024 included in the Company’s Annual Report on Form 10-K contain an audit opinion from the Company’s independent registered public ...